Clinical Trials Logo

Filter by:
NCT ID: NCT06385405 Not yet recruiting - Clinical trials for Major Depressive Disorder (MDD)

Electroencephalography-based Precise Repetitive Transcranial Magnetic Stimulation Treatment

Start date: May 2024
Phase: N/A
Study type: Interventional

This study will focus on the hypothesis that repetitive transcranial magnetic stimulation (TMS) based on EEG personalized modulation may be more effective in promoting symptomatic relief of major depressive disorder (MDD), and will rely on the platform of neuroimaging and function brain imaging of Shanghai Mental Health Center (SMHC), an authoritative institution in the field of mental health. We will eventually facilitate optimization of physical therapy for major depressive disorder (MDD).

NCT ID: NCT06385379 Recruiting - Clinical trials for Aortic Arch Aneurysm

Guo's Aortic Arch Reconstruction: A Multicenter, Prospective Study of the Novel WeFlow-Tribranch System (GENIUS Study)

Start date: April 30, 2024
Phase: N/A
Study type: Interventional

A prospective ,Multiple Center Study About the Safety and Efficacy of WeFlow-Tribranch Embedded Aortic Triple-branch Arch Stent Graft System manufactured by EndoNom Medtech (Hangzhou) Co., Ltd. for true/pseudo aortic arch aneurysms and ulcers involving aortic arch . (GENIUS Study)

NCT ID: NCT06385158 Recruiting - Healthy Volunteer Clinical Trials

A Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Oral Dose Escalation of GS1-144 Tablets and the Effects of Food on the Pharmacokinetics of GS1-144 in a Chinese Population

Start date: April 2024
Phase: Phase 1
Study type: Interventional

A Phase I clinical study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple oral dose escalation of GS1-144 tablets and the effects of food on the pharmacokinetics of GS1-144 in a Chinese population

NCT ID: NCT06385145 Not yet recruiting - Clinical trials for Pediatric Growth Hormone Deficiency (PGHD)

A Bioavailability Study of Two Different PEG-rhGH Preparations.

Start date: May 8, 2024
Phase: Phase 1
Study type: Interventional

The purpose of this study is to compare the pharmacokinetics of the two different PEG-rhGH preparations.

NCT ID: NCT06385093 Not yet recruiting - Clinical trials for Rheumatoid Arthritis

A Study on the Prevention and Treatment of GIOP With Eldecalcitol

ELEGANT
Start date: June 2024
Phase: Phase 4
Study type: Interventional

The study will be a multi-center, randomized, open label, parallel trial conducted in rheumatoid arthritis patients treated with glucocorticoids. After signing the informed consent, all patients will be screened as per the inclusion and exclusion criteria. Estimated 314 eligible patients will be enrolled. The enrolled patients will be randomly assigned to either Eldecalcitol group or Alfacalcidol group in a 1:1 ratio and followed up for 12 months. On-site follow up visits will be conducted at Month 6 and 12 after enrollment. The study is designed to evaluate the efficacy and safety of Eldecalcitol in preventing glucocorticoid-induced bone loss in rheumatoid arthritis patients.

NCT ID: NCT06384482 Recruiting - Clinical trials for Recurrent/Refractory Small Cell Lung Cancer Lung Large Cell Neuroendocrine Carcinoma

SNC115 Injections in Patients With Recurrent/Refractory Small Cell Lung Cancer and Lung Large Cell Neuroendocrine Carcinoma

Start date: April 30, 2024
Phase: Phase 1
Study type: Interventional

This study is a FIH dose escalation clinical study, with single arm, open label and design, in order to observe the preliminary safety and Pharmacokinetic of SNC115 Injection in participants with Recurrent/refractory small cell lung cancer and Lung large cell neuroendocrine carcinoma.

NCT ID: NCT06384118 Completed - Clinical trials for Type 2 Diabetes Mellitus

Effects of a Health Intervention on Hypoglycemic Coping : a Pilot Study

Start date: August 1, 2023
Phase: N/A
Study type: Interventional

From August 2023 to January 2024, 100 patients with type 2 diabetes who met the inclusion and exclusion criteria were selected from the endocrinology department of The purpose of this study was to construct a hypoglycemia coping intervention program for type 2 diabetic patients based on the IMB theory and to investigate the feasibility, acceptability, and initial effects of the program.

NCT ID: NCT06383923 Recruiting - Clinical trials for Placenta Accreta Spectrum

Risk Factors, Prognosis and Prediction Models for Placenta Accreta Without Prior Cesarean Section

Start date: January 1, 2023
Phase:
Study type: Observational

1. Identify the risk factors for Placenta accreta spectrum (PAS) disorders in women without prior caesarean section (CS). 2. Clarify the prognostic factors of the disease and explore individualized treatment options to improve the prognosis of patients with this type of disease; 3. Use the cohort's biological sample database to conduct serology, cytology, and histology studies to explore the abnormal uterine immune microenvironment and the impact on uterine spiral artery remodeling in non-scar uterine-placenta accreta disease.

NCT ID: NCT06383897 Not yet recruiting - Healthy Clinical Trials

Phase 1 Study in Healthy Participants and Participants With Kidney Dysfunction

Start date: May 31, 2024
Phase: Phase 1
Study type: Interventional

A randomized, double-blind, placebo-controlled, dose-escalation clinical trial to evaluate the safety, tolerability, pharmacokinetic characteristics, and the impact of food on pharmacokinetics of oral HS-10398 in Chinese healthy participants, and a clinical trial to assess the pharmacokinetic characteristics of oral HS-10398 in Chinese participants with kidney dysfunction

NCT ID: NCT06383858 Recruiting - Preeclampsia Clinical Trials

The Project of Gestational Hypertension and Preeclampsia Screening and Prevention Center

Start date: August 1, 2023
Phase:
Study type: Observational

Preeclampsia is the main cause of illness and death in pregnant women and fetuses. Currently, there is no effective treatment for preeclampsia in clinical practice, and the fundamental treatment is still termination of pregnancy and placental delivery. Therefore, early prediction of preeclampsia and targeted strengthening of high-risk pregnant women supervision, early intervention and diagnosis and treatment can greatly reduce the serious obstetric complications and perinatal maternal and fetal deaths caused by preeclampsia, which has significant social and clinical significance.